Literature DB >> 24452084

The level of complement C3 is associated with the severity of atherosclerosis but not with arterial calcification in peripheral artery disease.

M Fehérvári1, M Krepuska, G Széplaki, A Apor, P Sótonyi, Z Prohászka, G Acsády, Z Szeberin.   

Abstract

AIM: Recent evidences show correlations between atherosclerosis and the serum level of third component of complement (C3). However, there is less data on the connection of C3 and the severity of atherosclerosis. The aim of our study was to evaluate the association of serum C3 levels with atherosclerosis and arterial calcification in patients with chronic lower extremity atherosclerosis.
METHODS: In a single centre cross-sectional study 103 patients and 109 healthy controls were examined. Sera were analyzed for C3. To identify the severity of atherosclerosis and calcification, ankle-brachial Doppler index, angiographic Bollinger score, arterial calcification score and carotid intima-media thickness was determined.
RESULTS: Serum level of C3 was significantly higher in the lower extremity atherosclerosis group than in healthy patients (P=0.00004). In the patient group, serum level of C3, C4 was significantly and inversely associated with ABI (r=-0.246, P=0.014), (r=-0.259, P=0.011). C3 inversely correlates with Bollinger score (r= -0.357, P=0.028). Among our patients no correlation was found between C3 levels and CS (P=0.672, r=-0.046) or between C3 levels and carotid IMT (r=0.104, P=0.351). The serum levels of different complement components were associated with C-reactive protein, Hba1c, peptide-C and insulin.
CONCLUSION: Our results suggest that C3 serum levels are associated with ABI and angiographic parameters of atherosclerosis, but do not relate to the severity of calcification.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24452084

Source DB:  PubMed          Journal:  Int Angiol        ISSN: 0392-9590            Impact factor:   2.789


  4 in total

1.  Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics.

Authors:  Liang-Hui Chu; Brian H Annex; Aleksander S Popel
Journal:  Front Pharmacol       Date:  2015-08-25       Impact factor: 5.810

2.  Down-regulation of Suv39h1 attenuates neointima formation after carotid artery injury in diabetic rats.

Authors:  Jing Zhang; Jian Yang; Changwu Xu; Qi Hu; Jun Hu; Jing Chen; Hong Jiang
Journal:  J Cell Mol Med       Date:  2019-11-17       Impact factor: 5.310

Review 3.  Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes.

Authors:  Grzegorz K Jakubiak; Natalia Pawlas; Grzegorz Cieślar; Agata Stanek
Journal:  Int J Environ Res Public Health       Date:  2021-11-15       Impact factor: 3.390

4.  Novel interactomics approach identifies ABCA1 as direct target of evodiamine, which increases macrophage cholesterol efflux.

Authors:  Limei Wang; Pierre Eftekhari; Daniel Schachner; Irena D Ignatova; Veronika Palme; Nicole Schilcher; Angela Ladurner; Elke H Heiss; Herbert Stangl; Verena M Dirsch; Atanas G Atanasov
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.